Today: 13 June 2026
Bank of America (BAC) stock today: Shares slip as Fed minutes, year-end funding strains grab focus
30 December 2025
1 min read

Bank of America (BAC) stock today: Shares slip as Fed minutes, year-end funding strains grab focus

NEW YORK, December 30, 2025, 11:54 ET — Regular session

Bank of America Corp shares were down 0.2% at $55.23 by 11:54 a.m. ET, after trading between $55.20 and $55.64. About 6.5 million shares had changed hands.

The move came as U.S. stocks edged lower in thin year-end trading, with technology weakness and a softer financial sector weighing on major indexes. “I wouldn’t try to make too much out of anything that happens in a holiday-shortened week and very light trading volume,” said Art Hogan, chief market strategist at B Riley Wealth. Investors were also waiting for minutes from the Federal Reserve’s December meeting, due later on Tuesday, for fresh clues on the 2026 rate path. Reuters

Money-market signals added to the caution. Banks borrowed $25.95 billion on Monday from the Fed’s standing repo facility — an overnight backstop that lends cash against Treasuries or mortgage-backed securities — one of the largest uses since the tool began in 2021, New York Fed data showed.

Big-bank peers also eased, pointing to a sector move more than a Bank of America-specific headline. JPMorgan Chase was down 0.1%, Wells Fargo slipped 0.3% and Citigroup fell about 1.0%.

On the policy backdrop, Bank of America CEO Brian Moynihan said the administration’s trade push was showing signs of de-escalation and that tariffs were clustering around roughly 15% for many countries, in a CBS News “Face the Nation” interview aired Sunday. Business Insider

That matters for large lenders because corporate clients often slow borrowing and dealmaking when trade rules are unclear. Clearer policy can also help stabilize credit conditions for companies exposed to import costs and supply chains.

Rates remain the bigger lever for bank stocks. Bank of America’s earnings are closely tied to net interest income — what it earns on loans and securities minus what it pays out on deposits — which can swing with shifts in Fed-cut expectations.

The shares closed Monday down 1.46% at $55.35, according to the bank’s investor relations data, leaving the stock to start Tuesday’s session with a cautious tone.

Traders now want to see whether the Fed minutes read as a green light for faster easing in 2026, or a sign policymakers still want more proof the labor market is cooling. Any repeat of year-end strain in funding markets could also keep bank shares sensitive to moves in short-term rates.

The next clear company catalyst is earnings. Bank of America is scheduled to report fourth-quarter 2025 results on Jan. 14, 2026, the bank said.

Investors typically watch management’s outlook for net interest income, deposit pricing and credit costs, along with trading and investment-banking trends as markets reset for the new year. Guidance on expense control and capital returns can also move the stock quickly.

For now, Bank of America’s tape looks driven by the rate narrative and year-end liquidity, with light holiday volume amplifying small shifts.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Orla Mining (ORLA) stock edges higher as gold rebounds; Fed minutes in focus
Next Story

Orla Mining (ORLA) stock edges higher as gold rebounds; Fed minutes in focus

Go toTop